As governments and the private sector shift focus on the medicinal benefits of cannabis-derived drugs, many cannabis companies expect more favourable legal changes, which may ultimately provide a further boost to the industry.
That said, the bulk of US revenues come from non-American markets. They’re multinationals, so up to 43% of their profits are earned in foreign lands, according to stats in 2016. Also, a good number of companies listed in
US exchanges are global. This means both in the literal and metaphorical sense, adding US shares to your portfolio offers instant diversification benefits. In these discussions, US investment is often pitted against China.